Literature DB >> 22531375

Substance P-induced changes in cell genesis following diffuse traumatic brain injury.

H L Carthew1, J M Ziebell, R Vink.   

Abstract

Inhibition of substance P (SP) activity through the use of NK1 receptor antagonists has been shown to be a promising neuroprotective therapy following traumatic brain injury (TBI). Conversely, recent research has implicated SP in the stimulation of neurogenesis, suggesting that the neuropeptide has the potential to promote recovery following TBI. This study characterised the effects of SP and the NK1 antagonist, n-acetyl tryptophan (NAT), on cell proliferation following diffuse TBI. Adult male Sprague-Dawley rats were injured using the impact acceleration model of TBI and randomly assigned to one of five treatment groups: sham, vehicle control, NAT alone, SP alone or SP with NAT. Cellular proliferation was assessed with immunostaining for bromodeoxyuridine (BrdU) and cell-specific markers. Infusion of SP (±NAT) promoted cellular proliferation in the subventricular zone and dentate gyrus following TBI. This increase was largely associated with microglial proliferation and did not correspond with functional improvements. These results suggest that NAT treatment results in neuroprotection following TBI, mediated in part via inhibition of microglia.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531375     DOI: 10.1016/j.neuroscience.2012.04.028

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  13 in total

Review 1.  Combination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better?

Authors:  Anthony E Kline; Jacob B Leary; Hannah L Radabaugh; Jeffrey P Cheng; Corina O Bondi
Journal:  Prog Neurobiol       Date:  2016-05-07       Impact factor: 11.685

2.  Substance P stimulates endothelin 1 secretion via endothelin-converting enzyme 1 and promotes melanogenesis in human melanocytes.

Authors:  Phil June Park; Tae Ryong Lee; Eun-Gyung Cho
Journal:  J Invest Dermatol       Date:  2014-09-30       Impact factor: 8.551

Review 3.  Inflammation in acute CNS injury: a focus on the role of substance P.

Authors:  F Corrigan; R Vink; R J Turner
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

4.  Neurologic impairment following closed head injury predicts post-traumatic neurogenesis.

Authors:  L E Villasana; G L Westbrook; E Schnell
Journal:  Exp Neurol       Date:  2014-05-23       Impact factor: 5.330

Review 5.  Microglia: dismantling and rebuilding circuits after acute neurological injury.

Authors:  Jenna M Ziebell; P David Adelson; Jonathan Lifshitz
Journal:  Metab Brain Dis       Date:  2014-04-15       Impact factor: 3.584

6.  Serum substance P levels are associated with severity and mortality in patients with severe traumatic brain injury.

Authors:  Leonardo Lorente; María M Martín; Teresa Almeida; Mariano Hernández; Luis Ramos; Mónica Argueso; Juan J Cáceres; Jordi Solé-Violán; Alejandro Jiménez
Journal:  Crit Care       Date:  2015-04-27       Impact factor: 9.097

Review 7.  The Role of Neurogenic Inflammation in Blood-Brain Barrier Disruption and Development of Cerebral Oedema Following Acute Central Nervous System (CNS) Injury.

Authors:  Annabel J Sorby-Adams; Amanda M Marcoionni; Eden R Dempsey; Joshua A Woenig; Renée J Turner
Journal:  Int J Mol Sci       Date:  2017-08-17       Impact factor: 5.923

8.  Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.

Authors:  Kate Marie Lewis; Renée Jade Turner; Robert Vink
Journal:  Int J Inflam       Date:  2013-05-29

9.  Rod microglia: a morphological definition.

Authors:  Samuel E Taylor; Cristina Morganti-Kossmann; Jonathan Lifshitz; Jenna M Ziebell
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

Review 10.  New Prognostic Biomarkers in Patients With Traumatic Brain Injury.

Authors:  Leonardo Lorente
Journal:  Arch Trauma Res       Date:  2015-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.